The Specimen Core has been developed to meet the needs of the investigators involved in the Immunologic Monitoring Consortium (IMC) projects and pilot projects with respect to specimen and reagent acquisition, characterization, and distribution. In addition, a primary goal of the specimen core is the development of a large lymphocyte and sera repository that will ultimately serve as a resource for scientists outside the realm of the IMC. The advantages of an organized and comprehensive approach to specimen collection and characterization are two-fold. First, a systematic process for specimen collection and review will ensure quality and consistency in the analysis to be performed in different laboratories. Second, centralized management of specimens will facilitate their distribution based on the priorities defined by the investigators in the projects and administrative core.
The specific aims of the specimen core are to: (1) recruit volunteer blood donors and cancer patients for leukapheresis, collect, process, store, and ship samples, (2) clone and characterize tumor and viral antigen specific T cells from donors and supply to investigators for validation studies, (3) breed transgenic animals, perform vaccination and/or protection experiments, and coordinate shipping of immune spleens and sera to investigators, (4) develop standard operating procedures (SOP) for the consortium, obtain and standardize protein sources and other shared resources and distribute to investigators, and, (5) coordinate sample acquisition and shipping of samples relating to cancer vaccine clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA090818-02
Application #
6563977
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-02-19
Project End
2002-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
2
Fiscal Year
2002
Total Cost
$296,752
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Slota, Meredith; Lim, Jong-Baeck; Dang, Yushe et al. (2011) ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines 10:299-306
Coveler, Andrew L; Goodell, Vivian; Webster, Devon J et al. (2009) Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity. Breast Cancer Res Treat 113:95-100
Maecker, Holden T (2009) Multiparameter flow cytometry monitoring of T cell responses. Methods Mol Biol 485:375-91
Ladd, Jon; Lu, Hailing; Taylor, Allen D et al. (2009) Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor. Colloids Surf B Biointerfaces 70:1-6
Maecker, Holden T; Hassler, Jeffrey; Payne, Janice K et al. (2008) Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol 9:9
Goodell, Vivian; Waisman, James; Salazar, Lupe G et al. (2008) Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 7:449-54
Park, Kyong Hwa; Gad, Ekram; Goodell, Vivian et al. (2008) Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res 68:8400-9
Goodell, Vivian; McNeel, Douglas; Disis, Mary L (2008) His-tag ELISA for the detection of humoral tumor-specific immunity. BMC Immunol 9:23
Siebert, Janet C; Inokuma, Margaret; Waid, Dan M et al. (2008) An analytical workflow for investigating cytokine profiles. Cytometry A 73:289-98
Goodell, Vivian; dela Rosa, Corazon; Slota, Meredith et al. (2007) Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses. BMC Immunol 8:21

Showing the most recent 10 out of 23 publications